Use of cytomegalovirus antigenemia as a marker for preemptive treatment

Transplant Proc. 2002 Feb;34(1):67-8. doi: 10.1016/s0041-1345(01)02668-9.
No abstract available

MeSH terms

  • Administration, Oral
  • Adult
  • Antigens, Viral / blood*
  • Biomarkers / blood
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy*
  • Drug Therapy, Combination
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Injections, Intravenous
  • Kidney Transplantation / immunology*
  • Phosphoproteins / blood
  • Postoperative Complications / virology*
  • Viral Matrix Proteins / blood

Substances

  • Antigens, Viral
  • Biomarkers
  • Immunosuppressive Agents
  • Phosphoproteins
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa
  • Ganciclovir